Nasdaq Closes Delisting Matter as Alaunos Regains $2.5M Equity Compliance
TCRT has more than doubled off its 52-week low of $0.719 on light trading volume (0.2× avg).
Summary
Nasdaq confirmed Alaunos regained compliance with the $2.5 million stockholders' equity requirement, closed the delisting matter and cancelled the November 10 hearing, so TCRT stays listed on the Nasdaq Capital Market.
Key Events · Corporate Governance and Compliance · TCRT
-
Nasdaq Closes Delisting Matter
On October 22, 2026, Nasdaq's Office of General Counsel confirmed the company had regained compliance with the $2,500,000 Stockholders' Equity Requirement; the matter is closed and the November 10, 2026 Hearings Panel hearing is cancelled.
-
Listing on Nasdaq Capital Market Continues
Common stock will continue to be listed and traded on The Nasdaq Capital Market, removing the immediate delisting overhang.
-
Compliance Tied to October Private Placement
The company had previously stated it believed it regained compliance as a result of the October 14, 2026 completion of its private placement financing.
-
10-K Compliance Check Remains
The filing warns that if compliance is not evidenced in the Annual Report on Form 10-K for fiscal year 2026, the company may again be subject to delisting.
Analysis · TCRT · Life Sciences
The most pressing overhang — a live Nasdaq delisting proceeding with a November 10 hearing — has been removed. Following the October 14 private placement close, Nasdaq's Office of General Counsel confirmed the company is back above the $2,500,000 stockholders' equity requirement, closed the matter, and cancelled the hearing. The stock retains its Nasdaq Capital Market listing, which removes forced-sale and liquidity risk for holders. It does not, however, fix the underlying business: compliance rests on the equity raised in the Velaris merger financing, and the filing itself flags that if compliance is not evidenced in the 2026 10-K, delisting risk returns.
How filings like this one have moved
In the 30 days to Oct 24, 2026, 29.5% of the 1521 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.14%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TCRT was trading at $2.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $0.72 to $4.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.